Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Moore

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
EPR25-121: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Cancer Patients: Testing and Referral GuidelinesTeodora Kuzmanovic, Maedeh Zoakei Nikoo, Sindhusha Veereballi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
JCO Clinical Cancer Informatics|June 23, 2023
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME ModelSibel Blau, Julio Antonio Peguero, Halle C F Moore, et al.
JAMA Network Open|May 4, 2023
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast CancerRikki A Cannioto, Kristopher M Attwood, Evan W Davis, et al.
Cancers|August 12, 2023
Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-OmicsLisa Welter, Serena Zheng, Sonia Maryam Setayesh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2019
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)Christine B Ambrosone, Gary R Zirpoli, Alan D Hutson, et al.
Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
EPR25-121: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Cancer Patients: Testing and Referral GuidelinesTeodora Kuzmanovic, Maedeh Zoakei Nikoo, Sindhusha Veereballi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
JCO Clinical Cancer Informatics|June 23, 2023
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME ModelSibel Blau, Julio Antonio Peguero, Halle C F Moore, et al.
JAMA Network Open|May 4, 2023
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast CancerRikki A Cannioto, Kristopher M Attwood, Evan W Davis, et al.
Cancers|August 12, 2023
Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-OmicsLisa Welter, Serena Zheng, Sonia Maryam Setayesh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2019
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)Christine B Ambrosone, Gary R Zirpoli, Alan D Hutson, et al.
Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.
Pageof 17